ESSA Pharma Inc (EPI) Given “Buy” Rating at Dawson James
Separately, Bloom Burton reaffirmed a “buy” rating on shares of ESSA Pharma in a research note on Thursday, May 18th.
ESSA Pharma (EPI) opened at 0.45 on Wednesday. The firm’s market cap is $13.09 million. ESSA Pharma has a 52 week low of $0.38 and a 52 week high of $4.60. The firm’s 50 day moving average price is $0.62 and its 200-day moving average price is $2.31.
ESSA Pharma Company Profile
ESSA Pharma Inc is a Canada-based clinical-stage development pharmaceutical company. The Company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer (CRPC). The Company is developing drugs, which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR).
Receive News & Ratings for ESSA Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.